LILRB4 as a novel immunotherapeutic target for multiple diseases
Xu Wang(Jiangsu University), Ming Shi(Xuzhou Medical College), Rui Hou(Xuzhou Medical College), Junnian Zheng(Xuzhou Medical College), Lanying Li(North Sichuan Medical University), Dan Liu(General Hospital of Shenyang Military Region), Zhangchun Guan, Xuan Zhao(People's Hospital of Xinjiang Uygur Autonomous Region), Sijin Li(Xuzhou Medical College), Yuhang Jin(Jilin University), Ming Lu(Hangzhou DAC Biotech (China)), Wen Ma(Xuzhou Medical College)
Cited by 4
Related Papers
Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment
|Oncotarget|2018|217
DNA damage response – A double-edged sword in cancer prevention and cancer therapy
|Cancer Letters|2014|189
The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects
|Frontiers in Immunology|2024|136
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
|Journal of Hematology & Oncology|2018|134
CHCHD2 inhibits apoptosis by interacting with Bcl-x L to regulate Bax activation
|Cell Death and Differentiation|2014|116